LT3810626T - Pcsk9 antagonistų junginiai - Google Patents

Pcsk9 antagonistų junginiai

Info

Publication number
LT3810626T
LT3810626T LTEPPCT/US2019/038155T LTUS2019038155T LT3810626T LT 3810626 T LT3810626 T LT 3810626T LT US2019038155 T LTUS2019038155 T LT US2019038155T LT 3810626 T LT3810626 T LT 3810626T
Authority
LT
Lithuania
Prior art keywords
antagonist compounds
pcsk9 antagonist
pcsk9
compounds
antagonist
Prior art date
Application number
LTEPPCT/US2019/038155T
Other languages
English (en)
Lithuanian (lt)
Inventor
Harold Wood
Hubert Josien
Thomas Tucker
Angela Kerekes
Ling Tong
Abbas WALJI
Anilkumar NAIR
Fa-Xiang Ding
Elisabetta Bianchi
Danila Branca
Chengwei WU
Yusheng Xiong
Sookhee Ha
Jian Liu
Sobhana Boga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LT3810626T publication Critical patent/LT3810626T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2019/038155T 2018-06-21 2019-06-20 Pcsk9 antagonistų junginiai LT3810626T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21
PCT/US2019/038155 WO2019246349A1 (en) 2018-06-21 2019-06-20 Pcsk9 antagonist compounds

Publications (1)

Publication Number Publication Date
LT3810626T true LT3810626T (lt) 2025-11-10

Family

ID=67263083

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/038155T LT3810626T (lt) 2018-06-21 2019-06-20 Pcsk9 antagonistų junginiai

Country Status (38)

Country Link
US (3) US11427616B2 (cg-RX-API-DMAC10.html)
EP (2) EP4660303A3 (cg-RX-API-DMAC10.html)
JP (3) JP7112531B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250161677A (cg-RX-API-DMAC10.html)
CN (2) CN112313243B (cg-RX-API-DMAC10.html)
AR (1) AR115597A1 (cg-RX-API-DMAC10.html)
AU (2) AU2019290163C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020025274A8 (cg-RX-API-DMAC10.html)
CA (1) CA3102629A1 (cg-RX-API-DMAC10.html)
CL (2) CL2020003257A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021000456A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210031A (cg-RX-API-DMAC10.html)
DK (1) DK3810626T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2020000250A (cg-RX-API-DMAC10.html)
EA (1) EA202190086A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21003643A (cg-RX-API-DMAC10.html)
ES (1) ES3047399T3 (cg-RX-API-DMAC10.html)
FI (1) FI3810626T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20237506B (cg-RX-API-DMAC10.html)
HR (1) HRP20251302T1 (cg-RX-API-DMAC10.html)
HU (1) HUE073367T2 (cg-RX-API-DMAC10.html)
IL (2) IL279363B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20190150A1 (cg-RX-API-DMAC10.html)
LT (1) LT3810626T (cg-RX-API-DMAC10.html)
MA (1) MA52967B1 (cg-RX-API-DMAC10.html)
MD (1) MD3810626T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020013726A (cg-RX-API-DMAC10.html)
NI (1) NI202000101A (cg-RX-API-DMAC10.html)
PE (1) PE20211584A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020552187A1 (cg-RX-API-DMAC10.html)
PL (1) PL3810626T3 (cg-RX-API-DMAC10.html)
PT (1) PT3810626T (cg-RX-API-DMAC10.html)
RS (1) RS67338B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202012451WA (cg-RX-API-DMAC10.html)
SI (1) SI3810626T1 (cg-RX-API-DMAC10.html)
TW (1) TWI840376B (cg-RX-API-DMAC10.html)
UA (1) UA129467C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019246349A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
EP3810129B1 (en) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Pcsk9 antagonist bicyclo-compounds
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
MX2024002146A (es) * 2021-08-19 2024-03-08 Merck Sharp & Dohme Llc Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
SI4540267T1 (sl) 2022-06-15 2026-07-31 Merck Sharp & Dohme Llc Ciklični peptidi za ujetje interlevkina-1 beta
JP7866141B2 (ja) * 2022-08-17 2026-05-26 メルク・シャープ・アンド・ドーム・エルエルシー Pcsk9阻害薬の結晶形態、組成物及び使用
WO2024259310A2 (en) * 2023-06-15 2024-12-19 Merck Sharp & Dohme Llc Passive permeable pcsk9 antagonist compounds
IL328311A (en) 2023-11-14 2026-07-01 Merck Sharp & Dohme Llc Cyclic peptide for capturing Interleukin-1 Beta
AU2024401721A1 (en) 2023-12-15 2026-07-16 Merck Sharp & Dohme Llc A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2025264781A1 (en) * 2024-06-18 2025-12-26 Kemira Oy J Cationizing agents for saccharides and methods
WO2026019622A1 (en) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Crystal forms of a cyclictetrapeptide and processes for preparing
WO2026019624A1 (en) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Synthesis of cyclic oligopeptides
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术(石家庄)有限公司 环肽类似物及其制备方法和用途
WO2026034639A1 (ja) * 2024-08-09 2026-02-12 株式会社Spin Wave ペプチド合成用可溶性担体およびこれを用いた合成方法
CN119930471A (zh) * 2024-12-31 2025-05-06 苏州默迪夫生物科技有限公司 Mk-a的制备方法、所用的中间体及其合成方法
CN122464947A (zh) * 2025-01-25 2026-07-28 深圳市祥根生物有限公司 一种环肽类pcsk9抑制剂和用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
US4656269A (en) 1986-04-15 1987-04-07 Kissei Pharmaceutical Co., Ltd. Histidine derivatives
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2512879A1 (en) 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EP2174343A1 (en) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Manufacturing method of semiconductor device
US20100179173A1 (en) 2007-06-28 2010-07-15 Daniel Guay Substituted fused pyrimidines as antagonists of gpr105 activity
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
NZ612544A (en) 2010-12-28 2015-04-24 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
MX2013009258A (es) * 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションShifa Biomedical Corporation 抗プロタンパク質転換酵素サブチリシン/ケキシン9型(抗pcsk9)化合物および心血管疾患の治療および/または予防におけるその使用方法
MX373298B (es) 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016119067A1 (en) 2015-01-30 2016-08-04 Pronasci Inc. Peptides derived from human pcsk9 catalytic domain and uses there of for promoting ldl-r activity
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами
CN107286158A (zh) 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3442991A4 (en) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
AU2017281332A1 (en) 2016-06-24 2018-12-20 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
CN109284823B (zh) 2017-04-20 2020-08-04 上海寒武纪信息科技有限公司 一种运算装置及相关产品
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
WO2019246405A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
EP3810129B1 (en) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Pcsk9 antagonist bicyclo-compounds
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds

Also Published As

Publication number Publication date
SI3810626T1 (sl) 2025-12-31
JP2022141879A (ja) 2022-09-29
JP7112531B2 (ja) 2022-08-03
BR112020025274A2 (pt) 2021-03-09
HRP20251302T1 (hr) 2025-12-19
AU2022259744B2 (en) 2024-07-11
US12209145B2 (en) 2025-01-28
ECSP21003643A (es) 2021-02-26
ES3047399T3 (en) 2025-12-03
US20190389909A1 (en) 2019-12-26
MA52967A (fr) 2021-04-28
IL279363B1 (en) 2025-08-01
WO2019246349A1 (en) 2019-12-26
SG11202012451WA (en) 2021-01-28
EA202190086A1 (ru) 2021-05-18
EP4660303A2 (en) 2025-12-10
PL3810626T3 (pl) 2025-12-22
IL321719A (en) 2025-08-01
AU2022259744A1 (en) 2022-12-01
CR20210031A (es) 2021-02-11
PT3810626T (pt) 2025-10-15
DK3810626T3 (da) 2025-08-18
EP3810626A1 (en) 2021-04-28
US20250206781A1 (en) 2025-06-26
AU2019290163A1 (en) 2021-01-07
CN112313243A (zh) 2021-02-02
US11427616B2 (en) 2022-08-30
KR20250161677A (ko) 2025-11-17
EP3810626B1 (en) 2025-07-23
MX2020013726A (es) 2021-03-02
CL2020003257A1 (es) 2021-07-23
MD3810626T2 (ro) 2025-12-31
MA52967B1 (fr) 2025-09-30
RS67338B1 (sr) 2025-11-28
PH12020552187A1 (en) 2021-07-26
CN112313243B (zh) 2025-09-02
CL2022000027A1 (es) 2022-08-19
TW202019950A (zh) 2020-06-01
JP2025041712A (ja) 2025-03-26
BR112020025274A8 (pt) 2023-02-14
CN121130044A (zh) 2025-12-16
JP7855670B2 (ja) 2026-05-08
AU2019290163B2 (en) 2022-08-04
JP2021522311A (ja) 2021-08-30
NI202000101A (es) 2021-05-28
CO2021000456A2 (es) 2021-01-29
KR20210024035A (ko) 2021-03-04
DOP2020000250A (es) 2021-02-28
AR115597A1 (es) 2021-02-03
KR102884527B1 (ko) 2025-11-13
HUE073367T2 (hu) 2026-01-28
US20230159592A1 (en) 2023-05-25
CA3102629A1 (en) 2019-12-26
GEP20237506B (en) 2023-05-25
EP4660303A3 (en) 2026-02-25
PE20211584A1 (es) 2021-08-18
FI3810626T3 (fi) 2025-10-21
TWI840376B (zh) 2024-05-01
UA129467C2 (uk) 2025-05-07
JP7607615B2 (ja) 2024-12-27
WO2019246349A8 (en) 2021-02-04
JOP20190150A1 (ar) 2019-12-21
IL279363B2 (en) 2025-12-01
IL279363A (en) 2021-01-31
AU2019290163C1 (en) 2022-11-03
GEAP202215540A (en) 2022-12-12

Similar Documents

Publication Publication Date Title
DK3810626T3 (da) Pcsk9-antagonistforbindelser
IL292753A (en) Compounds
IL283639A (en) Kif18a inhibitors
IL283692A (en) Novel composition
LT3810602T (lt) Junginiai
MA54550A (fr) Inhibiteurs de kif18a
EP3843714C0 (en) CD73 INHIBITORS
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
MA52812A (fr) Inhibiteurs de sarm1
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA52813A (fr) Inhibiteurs de sarm1
EP3810129A4 (en) PCSK9 -ANTAGONISTIC BICYCLO COMPOUNDS
EP3801499A4 (en) INHIBITORS OF SARM1
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
HUE065134T2 (hu) Vegyületek
DK3737677T3 (da) Tetrahydroisoquinolinforbindelser
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
LT3867247T (lt) Naujieji junginiai
DK3808747T3 (da) Imidazopyridinon-forbindelse
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3902806C0 (en) THIENOPYRIDINONE COMPOUNDS
DK3738452T3 (da) Fordamper
EP3682831C0 (en) CRYOGENIC APPLICATOR
EP3833374C0 (en) PROTEASOME INHIBITORS